Fintel reports that on March 12, 2025, Wedbush downgraded their outlook for Arvinas (NasdaqGS:ARVN) from Outperform to ...

Despite the recent sell-off in tech stocks, analysts at Wedbush believe that this downturn is temporary and that AI leaders ...

Despite the recent rash of tech stock sell-offs, the analysts at Wedbush believe this is a short-term phenomenon, and the ...

Dan Ives, Wedbush Securities global head of technology research, joins CNBC's 'Squawk on the Street' to discuss outlooks on ...

Tesla (TSLA) stock has landed on Wedbush’s “best ideas list” as analyst Daniel Ives reaffirmed his bullish stance on the ...

Market fears over tariffs and growth have hit tech stocks, but Wedbush sees the dip as a buying opportunity for long-term investors ...

Just days after saying Tesla Inc.’s recent stock selloff was overdone, Wedbush analyst Dan Ives, a well-known tech analyst ...

Markets are still under a great deal of pressure. All thanks to more tariffs on Canada, Mexico, China and inflation threats, ...

Immunome (NASDAQ:IMNM – Get Free Report)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a research ...

Wedbush analysts called Palantir one of their "top names" to own in 2025, expecting the stock to benefit from a "tidal wave of spending on AI." ...

Wedbush reaffirmed their outperform rating on shares of Beam Therapeutics (NASDAQ:BEAM – Free Report) in a research note ...